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ScienceDirectProtein–protein interactions (PPI) have become increasingly
popular drug targets, with a number of promising compounds
currently in clinical trials. Recent research shows, that PPIs can
be modulated in more ways than direct inhibition, where novel
non-competitive modes of action promise a solution for the
difficult nature of PPI drug discovery.Here, we review recently
discovered PPI modulators in light of their mode of action and
categorise them as disrupting versus stabilising, orthosteric
versus allosteric and by their ability to affect the proteins’
dynamics. We also give recent examples of compounds
successful in the clinic, analyse their physicochemical
properties and discuss how to overcome the hurdles in
discovering alternative modes of modulation.
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Introduction
The interactome [1] has been predicted to contain some
130,000 binary protein–protein interactions (PPI) [2], which
regulate diverse intra-cellular and extracellular biological
processes including cell division, signalling, metabolic
pathways and the assembly of cellular machinery.
Given their importance to all aspects of biology, manipu-
lation of PPIs has immense potential for drug develop-
ment, but they have long been considered challenging to
drug by small ligands [3]. Protein–protein (PP) interfaces
tend to lack the deep pockets typical for enzyme active
sites, and small molecule inhibitors need to leverage
sufficient energy from small, shallow or exposed cavities
on the surface to compete against the much larger inter-
action areas used by natural protein ligands. Neverthe-
less, a number of novel PPI modulators are showing
encouraging results in both preclinical models and clinicalCurrent Opinion in Biotechnology 2015, 35:78–85 trials, and many general reviews on this topic have been
written recently [4,5,6].
PPIs are diverse in nature, and so are their modulators.
Several classifications are in use for PPI modulators,
reflecting their complexity. They have been categorised
based on the ligand type (small molecules vs. peptides vs.
macromolecules) [6], the peptide binding epitope that
the modulators are derived from (primary vs. secondary vs.
tertiary structures) [5], the calculated physicochemical
and pharmacological profiles [7], the presence of hot spots
and hot segments [8] and the topology of the interface [9].
Here we have collected recently reported small molecule
protein–protein modulators (see Table 1) and review their
mechanisms of action. In particular, we focus on the two
axes of orthosteric versus allosteric [10] and disruptive
versus stabilising [11] modes, and describe the effect
of interfacial binders on the function and dynamics of the
protein. We highlight selected examples of the different
PPI modulator categories going beyond inhibition by
direct competition (orthosteric inhibition) and discuss
the implications of the PPI modulation approach for the
future drug discovery projects. In addition, we review
secondary effects of binders on a protein’s dynamics and
downstream effects, which appear as a distinct way to
achieve specificity for difficult targets.
Modes of action
Protein–protein interactions can be modulated in a num-
ber of ways, with the main mechanistic classification
being a division into PPI disruptors and stabilisers. We
further divide these categories into orthosteric and allo-
steric, as illustrated in Figures 1,3. Protein complex
formation can be inhibited by either direct competition
at the interface (orthosteric disruptor, Figure 1a) or via
allosteric destabilisation of the PPI through a molecule
bound to the protein at a site remote to the interface
(allosteric disruptor, Figure 1b). Small molecules can also
impact PPIs by increasing PP affinity through binding to a
newly formed binding site at the PP interface (orthosteric
stabiliser). This site is formed by the two interaction
partners and typically located at the rim of the interface
(Figure 1c). Similarly to PPI disruptors, stabilisation of
PPIs can also be achieved by an allosteric affect (allosteric
stabiliser, Figure 1d).
The effect of interfacial binders is not limited to the
modulation of the PP binding affinity. Without necessari-
ly changing PP affinity, molecules can utilise bindingwww.sciencedirect.com
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Table 1
Protein–protein interaction modulators with structural data made available in 2012–2014. ‘# HA’ describes the average number of heavy
atoms, MW is the average molecular weight in g/mol, the ‘sp3-ratio’ is the ratio of sp3-centres per heavy atom, and the PDB ligand name
describes the three letter code used for the respective compounds in the Protein Data Bank, with commonly used names for compounds
in clinical trials in parentheses.
# HA MW [g/mol] sp3-ratio Disease area Ligand name in PDB (Clinical trial molecule name)
Orthosteric disruptors
Bcl-2 and Bcl-XL*/BH3 47.6 677.3 0.23 Cancer 1Y1 (ABT-199), 1XV, 1XJ (ABT-263), H1I, H0Y,
X8U, X0B, LC3, LC6, 38H
MDM2*/p53 38.4 565.7 0.33 Cancer 20Q, 20U, I09 (RG7388), NUT, 1F0 (RG7112)
Menin/MLL 28.4 401.5 0.55 Cancer 2S6, 2VK, 2S7, 2S, 2SE, 2SF, EPE, 0RO, 0RT
Cdc20/APC_C 27.0 438.7 0.19 Cancer WR7
Keap1/Cul3 36.0 493.7 0.67 Cancer SXJ
CaMBD/calmodulin 10.0 136.2 0.00 CNS,
cardiovascular
diseases
PHU
RPA70N 19.7 304.4 0.16 Cancer 2NL, ZCL, 1FJ
Rad51 11.3 151.8 0.07 Cancer 5H1, 5MI, 4ME, LZ1, ABV, TR7, 03, 1NP
PDK1/PIF 25.5 363.5 0.14 Cancer MJF, 21O
pVHL/HIF-1a 33.5 475.4 0.43 Cancer 3JG, 3JK, 3JT, 3JU, 3JV, 3JF, 3JS, 3JH, 3JO, 3JJ
ATAD2/Kac 13.9 194.4 0.33 Cancer 39O, 39R, 39U, 12Q, 38S, 38T, MB3, TDR, THM
BAZ2B/Kac 15.7 227.7 0.32 Cancer 2LW, 2LX, 2LY
BET BRD2-4/Kac* 23.1 336.5 0.21 Cancer,
atherosclerosis
1AJ, 1A9, 1A8, 1A7, 1A6, 1A5, 1A4, 1A3, 15E, 14Z,
14X, 13F, 0NS, WSH, EAM (i-BET762), 73B (I-BET726,
GSK1324726A), 9S3, 1K0 (RVX208)
CBP&P300/Kac 30.7 425.8 0.30 Cancer,
neurodegeneration
2LK, 2LO, 2LL
NMT 30.3 454.8 0.39 Infection EN5, EN5, JJ1, 7AH, A6K, A6M, UEK, VIQ, QMI,
2CB, 2CD, PS8
K-ras/Sos 23.4 352.6 0.26 Cancer BEN, 9LI, BZI, 0QW, 0QX, 0QV, 0QR, 0QY
PDEd/K-ras 34.0 445.5 0.12 Cancer 18F, 1M1, 1M0, 17X
Allosteric disruptors
K-ras/Sos 25.1 424.3 0.40 Cancer 20H, 20G, 21J, 21C, 21F, 21Y, 21K, 21M, 21S, 22C
Orthosteric stabilisers
Transthyretin* 20.5 300.2 0.12 Amyloidosis,
polyneuropathy
16V, 3MI (Tafamidis)
PMA2/14-3-3 33.5 450.4 0.03 Herbicide,
cancer
0MT, YR1
Allosteric stabilisers
CDC34A/Ubiquitin 29.0 442.3 0.31 Cancer U94
Interfacial dynamic modulators
HIV-1 integrase/LEDGF-p75* 29.0 416.7 0.27 Infection TQ2, LF9, TQX, 0L9, 4BI (BI-224436)
GluAN1/GluAN2 25.0 339.5 0.48 CNS disorders QEM
GluA2 dimer* 18.5 248.3 0.30 CNS disorders CX5 (CX516), MQR
DHP synthase dimer 17.0 249.7 0.16 Infection 2O6, 2O8, 6DH, Z13
* Indicates approved drugs or compounds that are currently in clinical trials.pockets generated by protein homo-oligomerisation or
hetero-oligomerisation to alter the dynamics of the indi-
vidual protein complex components (interfacial dynamic
modulators). This in turn impacts downstream properties
of the complex such as enzymatic activity [12], oligomer-
isation state [13–15] or channel opening [16] (Figure 2).
Orthosteric PPI disruptors
The majority of small molecule PPI inhibitors currently
in clinical trials belong to the class of orthosteric disrup-
tors and act on longstanding therapeutic targets such as
proteins of the IAP family [17], Bcl-2 family [18,19],
MDM2 [20–23], LFA-1 [24] and HIV integrase [5].www.sciencedirect.com Recently, bromodomains (BD) have moved into the focus
of cancer drug discovery programs due to the enticing
ability to control the activity of multiple genes activity
simultaneously. BDs are sensors of epigenetic modifica-
tions and recognise e-N-acetylated lysines (Kac) in a spe-
cific sequence context, for example, in histone tails. BDs
are found in more than 60 proteins including the BET
family which regulates gene expression including thera-
peutically relevant oncogenes such as Myc [25], Bcl-2 [26]
and Aurora B [27], but also non-cancer targets like ApoA1
[28,29]. At the molecular level, all BET bromodomain
inhibitors bind to the Kac binding site competing with
the modified peptide ligand directly. As the orthostericCurrent Opinion in Biotechnology 2015, 35:78–85
80 Pharmaceutical biotechnology
Figure 2
oligomerisation
active site
modulation
(a) (b)
Current Opinion in Biotechnology
Schematic representation of secondary effects of interfacial binders
through protein dynamics. (a) An interfacial binder affecting the
oligomerisation of the protein complex, similar to HIV-integrase (see
text). (b) An interfacial binder allosterically changing the functionality of
the protein’s active site.
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Binding modes of modulators (orange) influencing PPIs. The affinity of
two proteins (blue/grey) can be decreased by either orthosteric (a) or
allosteric disruption (b), while stabilisation can occur through binding
at a composite site formed by the protein complex (c) or allosterically
(d). Note that all binding modes but (a) are non-competitive in nature.
Current Opinion in Biotechnology 2015, 35:78–85 inhibition of the BD-histone complex can both lead to an
increase and decrease in gene expression of a targeted
protein, phenotypic screening becomes essential.
The breakthrough for the rational drug design of BET
bromodomain inhibitors came from the discovery of the
pan-BET inhibitor (+)-JQ1 in 2010 [30]. While (+)-JQ1
has a broad activity against BET bromodomains, RVX-
208 shows narrower gene transcription modulation capac-
ity due to a higher specificity for binding BD2 over BD1
domains in the BET proteins, paving the way for a more
specific targeting of the transcription levels of individual
genes (Figure 3b) [28,31].
Since the discovery of (+)-JQ1 there has been remark-
ably fast progress in the development of the BD inhi-
bitors, with six small molecule modulators of BET
bromodomain having advanced into clinical trials: I-
BET762 (GSK525762a), I-BET726 (AZD3965),
OTX015, CPI-0610, Ten-010 and RVX-208 (see clin-
icaltrials.gov).
Allosteric PPI disruptors
Allosteric PPI disruptors modify PPI affinity by binding
to sites located distal to the PPI surface and provide an
attractive approach for targeting of PPI interfaces missing
deep cavities.
A biologically important complex to be modulated in this
way is the interaction of the c-Myc-MAX heterodimer, a
pleiotrophic transcription factor, which is involved in the
regulation of proliferation and hence interesting as an
anti-cancer target. Recent animal studies have shown that
disruption of the complex eradicate K-Ras-driven lung
tumours with minimal side effects [32]. A set of seven
compounds disrupting the c-Myc-MAX dimer has been
identified in a yeast two-hybrid screen [33]. Subsequent-
ly, Hammoudeh et al. [34] have shown by NMR experi-
ments that all these compounds bind to three distinct
sites on the c-Myc monomer, away from the c-Myc-MAX
interface, and disrupt the c-Myc-MAX heterodimer in an
allosteric manner.
A more recent example of allosteric disruptors is a set of
small molecules inhibiting small G-protein K-Ras. K-Ras
is a well-studied oncogene and one of the most frequently
mutated in cancers [35] and considered a good therapeu-
tic target. No K-Ras inhibitors acting directly against the
GTPase active site have been developed so far, but
attempts to modulate its PPI have been promising [36–
38].
Ostrem et al. have identified a number of small molecules
that allosterically inhibit GTP hydrolysis by K-Ras onco-
genic mutant G12C [39]. Crystallographic studies
revealed the inhibitors to be attached covalently to the
mutated cysteine in a previously unobserved pocket.www.sciencedirect.com
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Examples for PPI modulation. The small molecules are represented as a space filling model in orange, the individual proteins in blue and grey. (a)
Dimer of transthyretin stabilised by two molecules of Tafamidis (PDB: 3tct). (b) RVX-208 bound to the monomer of BRD2(BD2), preventing
interaction with peptide ligand (PDB: 4mr6). (c) Allosteric stabilisation of the Cdc34–Ubiquitin interaction through small molecule CC0651 (PDB:
4mdk). (d) Allosteric destabilisation of the KRas–Sos–interaction through a covalently attached inhibitor (PDB: 4lv6). The image is a
superpositioning of the apo-KRas/Sos-complex and the KRas-ligand complex. (e) Allosteric inhibitor at the interface of a DHPS-dimer, affecting its
intramolecular dynamics (PDB: 4nhv).
www.sciencedirect.com Current Opinion in Biotechnology 2015, 35:78–85
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anisms: stabilisation of the K-Ras-GDP form and disrup-
tion of the K-Ras interaction with its nucleotide exchange
factor Sos (Son of Sevenless) [40] (Figure 3d).
Orthosteric PPI stabilisers
Many PPIs are weak and transient [41], and both binding
and dissociation play a crucial role in the biology of the
complexes. Orthosteric stabilisers act directly at the in-
terface between the two proteins, thereby increasing the
stability of the complex. Well-known examples of orthos-
teric stabilisers are immunosuppressants rapamycin and
FK506 [4] isolated from Streptomycetaceae.
Another stabiliser in this class is Tafamidis, a drug for the
treatment of transthyrein-related hereditary amyloidosis.
Transthyretin (TTR) is a tetrameric protein which trans-
ports thyroxine and retinol in blood and cerebrospinal
fluid. Mutations of TTR and aging cause the tetramers to
misassemble into toxic extracellular amyloid structures
implicated in progressive neuro-myopathies or cardiomy-
opathies. Tafamidis ameliorates TTR amyloidosis by
acting as an orthosteric stabiliser of TTR dimers through
binding to the thyroxine-binding site located at the TTR
dimer–dimer interface [42,43] (Figure 3a). It inhibits fibril
formation by the wild type TTR and the two clinically
most significant amyloidogenic mutants V30M-TTR and
V122I-TTR. Recently, high throughput screening has
yielded another potent TTR modulator AG10 [44], which
stabilises both the clinically relevant mutant V122I and
the wild type TTR with comparable potency and efficacy.
Allosteric PPI stabilisers
Allosteric PPI stabilisation is common for small molecules
derived from natural compounds such as paclitaxel and
forskolin — both of which are being used in the clinic —
or tool compound brefeldin A [11]. By contrast, this
mechanism is rarely observed in rationally designed
drugs.
One protein amendable to allosteric stabilisation is E2
ubiquitin ligase Cdc34a. It mediates the conjugation of
ubiquitin to substrates of the cullin-RING ligases super-
family of E3 enzymes and is being targeted as part of the
ubiquitin–proteasome system for the treatment of cancer.
Recently, Huang et al. [45] have presented a novel
Cdc34a inhibitor that can be categorised as an allosteric
PPI stabiliser, albeit with a minor orthosteric contribu-
tion. The small molecule CC0651 stabilises the normally
weak enzyme–substrate complex between ubiquitin and
Cdc34a and thereby impedes ubiquitin transfer. CC0651
binds to a cryptic pocket in Cdc34a, trapping it in a more
stable conformation (Figure 3c). This allows tighter bind-
ing to ubiquitin due to increased shape complementarity
and lower flexibility. Notably, the targeted PPI surface
exhibits sequence variations across the E2 family and
stabilisation of the donor–ubiquitin–E2 interaction hasCurrent Opinion in Biotechnology 2015, 35:78–85 been suggested as a more general method to generate
specific E2 inhibitors [45].
Modulators of protein dynamics
The effect of binders to a newly formed pocket at PPI
interfaces is not limited to modifying the affinity between
the interacting proteins targeted. Instead, such interfacial
binders can also act as allosteric modulators of the indi-
vidual components of the protein complex by affecting
their dynamics, which is crucial to protein function [46]
and results in allosteric control of the protein function.
An example of interfacial dynamic modulators is a set of
inhibitors of dihydropteroatesynthase (DHPS), a dimeric
bacterial enzyme that is targeted by sulphonamide anti-
biotics, which have a number of undesired side effects
such as allergies or brain damage [12]. A fragment-based
approach yielded a low micromolar binder at the DHPS
dimer interface, which decreases both Km and Vmax of the
enzyme by two orders of magnitude. NMR and X-ray
crystallographic analysis in combination with Molecular
Dynamics (MD) simulations indicated an increased ri-
gidity of the protein upon inhibitor binding, suggesting a
dynamic linkage between the dimer interface and the
active site (Figure 3e).
Several examples of interfacial dynamic modulators have
also recently been described for HIV-1 integrase (HIV
IN) [12,14,15]. HIV IN is a homotetrameric protein
facilitating viral DNA integration into the host genome
and it is known to bind to the host protein lens endothelial
growth factor (LEDGF) that promotes viral DNA teth-
ering to the active chromatin [47]. Interfacial HIV IN
inhibitors have been shown to bind to the LEDGF
binding site located at a dimer interface. Interaction with
the LEDGF site resulted in a multimode, cooperative
mechanism of inhibition characterised by aberrant multi-
merisation of HIV IN that was incompatible with the viral
DNA binding, integrase 30-processing activity or disrup-
tion of chromatin tethering of HIV IN.
A third example of interfacial dynamic modulators is
RO25-6981 that binds to the N-methyl-D-aspartate
(NMDA) receptor, an ionotropic receptor controlling
synaptic plasticity and memory, and exhibits neuropro-
tective effects [48]. In the co-crystal structure of the
heterotetrameric GluN1–GluN2B receptor complex,
RO25-6981 is found at the receptor’s N-terminal domain
dimer interface, where it impairs the receptor subunit
dynamics, resulting in a reduced influx through the asso-
ciated ion channel located 90 A˚ away from the inhibitor
[16].
Conclusions and prospects
As we have highlighted in this review, there are a number
of underexplored mechanisms by which PPIs can be
modulated. Analysis of recent small molecules that affectwww.sciencedirect.com
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that about a third of the modulators employ modes of
action beyond the simple orthosteric inhibition (Table 1).
Notably, for some orthosteric (RVX-208) and for most of
the alternative modulators, the molecular mechanisms of
action on their corresponding targets (HIV IN, Cdc34a, c-
Myc, transthyretin, DHPS) have only been determined
retrospectively. It seems that the challenge in identifying
these alternative mechanisms lies in the design of assay
cascades that consider and monitor for unexpected out-
comes: alternative modes of action are easy to miss if you
do not know what you are looking for.
The good news is that we are not limited by technologies
for detecting either disruption or stabilisation of interac-
tions, as long as the assay is designed appropriately. In
order to identify and design effective PPI modulators, a
combination of functional, phenotypic and binding assays
is essential. A key role for rational design of PPI mod-
ulators falls to structural methods, in particular X-ray
crystallography and NMR, which provide atomic detail
of the respective binding modes and allow for rational
compound optimisation [49]. Here, engineering a protein
construct to expose the binding site, while simultaneously
not affecting unforeseen binding modes, is crucial [50].
Once the atomic structure of the protein-modulator com-
plex is known, computational methods have been ex-
tremely successful in the discovery of PPI inhibitors (for
example against BET and MDM2) [51,52]. Another
challenge is how to take advantage of transient or induced
pockets — while it is theoretically possible to predict
these through MD simulations, in practice structural data
of the relevant conformation is necessary for further
design.
The physicochemical properties of small molecules PPI
modulators and their suitability as drugs are an ongoing
debate. By contrast to inhibitors binding to active sites,
PPI modulators tend to be bigger and greasier [53,54].
However, our analysis of ten recent small molecules PPI
modulators currently in clinical trials revealed a broad
range of molecular sizes and complexity (Table 1): 18–65
heavy atoms, MW 241–974 Da, sp3-ratio 0–0.46, a log P
1.6–10.5, 3–8 rings, 1–6 hydrogen bond acceptors, 0–3
hydrogen bond donors. This diversity indicates that the
properties of PPI inhibitors heavily depend on the target
and the mode of action, and that rules are hard to define.
Several appealing properties speak in favour of modulation
by alternative mechanisms other than orthosteric inhibi-
tion. Alternative binding pockets are often smaller and
have reduced requirement for high-affinity binding be-
cause of their non-competitive nature, rendering them
appealing targets for small molecule inhibitor develop-
ment. In contrast to peptides or other macromolecules,
small molecules are arguably better suited to bind to the
newly formed composite binding sites. In addition, aimingwww.sciencedirect.com at the complex as opposed to the individual compo-
nents allows a decoupling of function from inhibitor
binding, which can lead to higher specificity and fewer
off-target effects. This concept is particularly relevant
for enzyme classes such as GTPases or kinases, where
specificity can be difficult to achieve due to conserva-
tion of active sites, but where interfaces between inter-
acting proteins can produce unique pockets for small
molecule modulation.
Overall, non-competitive binding modes appear to be a
promising strategy for targeting PPI with small molecules,
with a growing number of examples. The mechanisms
vary from target to target, and often sophisticated struc-
tural and biophysical characterisation is necessary to
define the modes of action. It is therefore important to
evaluate and explore these different, even opposite,
mechanisms of modulation of the target’s function at
the outset of drug discovery campaigns and screening
cascades should be designed in such a way that alternative
mechanisms of action can be captured and pursued ap-
propriately.
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